Literature DB >> 2542381

Selective expression of a normal action of the 1,25-dihydroxyvitamin D3 receptor in human skin fibroblasts with hereditary severe defects in multiple actions of that receptor.

J Barsony1, W McKoy, D A DeGrange, U A Liberman, S J Marx.   

Abstract

We evaluated three actions of 1,25-dihydroxycholecalciferol [1,25-(OH)2D3] in human skin fibroblasts to test for heterogeneity in hormone-response coupling. In fibroblasts from normal subjects the 1,25-(OH)2D3 concentrations for half-maximal effect (EC50) were: for mitogenic effect 0.0001-0.0005 nM, for antimitogenic effect 1 nM, and for induction of 25-OHD3 24-hydroxylase (24-OHase) 5 nM. To evaluate the effects of mutations presumed to be in the gene for the 1,25-(OH)2D3 receptor we examined cell lines representing four kindreds with hereditary resistance to 1,25-(OH)2D3 ("mutant" cell lines). In one mutant cell line all three 1,25-(OH)2D3 actions were severely abnormal. In one mutant cell line 24-OHase induction and mitogenic action were undetectable, but EC50 and maximal effect were normal for antimitogenic action of 1,25-(OH)2D3. In two mutant cell lines 24-OHase induction and antimitogenic actions were undetectable or severely impaired but mitogenic action were undetectable or severely impaired but mitogenic action was normal in EC50 and normal or increased in maximal effect. The mitogenic and antimitogenic actions in normal cells showed a similar profile of potency ratios for 1,25-(OH)2D3 and six analogues. Whenever a mutant cell showed a normal or even an abnormal mitogenic or antimitogenic effect of 1,25-(OH)2D3, these effects showed potency ratios similar to wild type, suggesting mediation by a similar 1,25-(OH)2D3 receptor. We conclude that three 1,25-(OH)2D3 actions show important differences in hormone response coupling indicated by differences in EC50 for 1,25-(OH)2D3 and by different consequences of receptor mutations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542381      PMCID: PMC303936          DOI: 10.1172/JCI114122

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells.

Authors:  D Dubik; R P Shiu
Journal:  J Biol Chem       Date:  1988-09-05       Impact factor: 5.157

2.  5'-flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3.

Authors:  T Okazaki; T Igarashi; H M Kronenberg
Journal:  J Biol Chem       Date:  1988-02-15       Impact factor: 5.157

3.  Estrogen-induced post-transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells.

Authors:  G F Santos; G K Scott; W M Lee; E Liu; C Benz
Journal:  J Biol Chem       Date:  1988-07-15       Impact factor: 5.157

4.  The N-terminal region of the chicken progesterone receptor specifies target gene activation.

Authors:  L Tora; H Gronemeyer; B Turcotte; M P Gaub; P Chambon
Journal:  Nature       Date:  1988-05-12       Impact factor: 49.962

5.  Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain.

Authors:  S Adler; M L Waterman; X He; M G Rosenfeld
Journal:  Cell       Date:  1988-03-11       Impact factor: 41.582

6.  1,25-Dihydroxyvitamin D3 increases epidermal growth factor receptors and transforming growth factor beta-like activity in a bone-derived cell line.

Authors:  P M Petkovich; J L Wrana; A E Grigoriadis; J N Heersche; J Sodek
Journal:  J Biol Chem       Date:  1987-10-05       Impact factor: 5.157

7.  Glucocorticoid-resistant lymphoma cell variants that contain functional glucocorticoid receptors.

Authors:  S K Rabindran; M Danielsen; M R Stallcup
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

8.  Differential effects of 1 alpha,25-dihydroxycholecalciferol and 24R,25-dihydroxycholecalciferol on the proliferation and the differentiated phenotype of rabbit costal chondrocytes in culture.

Authors:  M Takigawa; M Enomoto; E Shirai; Y Nishii; F Suzuki
Journal:  Endocrinology       Date:  1988-03       Impact factor: 4.736

9.  Steroid receptors, and the generation of closely coupled/biphasic dose-response curves.

Authors:  S J Quirk; J W Funder
Journal:  J Steroid Biochem       Date:  1988       Impact factor: 4.292

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  6 in total

Review 1.  International classification of osteochondrodysplasias. The International Working Group on Constitutional Diseases of Bone.

Authors:  J Spranger
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

2.  1,25(OH)2D3 receptor regulation and 1,25(OH)2D3 effects in primary cultures of growth cartilage cells of the rat.

Authors:  G Klaus; J Merke; H Eing; U Hügel; P Milde; H Reichel; E Ritz; O Mehls
Journal:  Calcif Tissue Int       Date:  1991-11       Impact factor: 4.333

3.  Differential metabolism of 25-hydroxyvitamin D3 by cultured synovial fluid macrophages and fibroblast-like cells from patients with arthritis.

Authors:  M E Hayes; D Bayley; P Still; J Palit; J Denton; A J Freemont; R G Cooper; E B Mawer
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

4.  Rapid accumulation of cyclic GMP near activated vitamin D receptors.

Authors:  J Barsony; S J Marx
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

5.  Effect of vitamin D on growth cartilage cell proliferation in vitro.

Authors:  G Klaus; R Meinhold-Heerlein; P Milde; E Ritz; O Mehls
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

6.  Immunocytology with microwave-fixed fibroblasts shows 1 alpha,25-dihydroxyvitamin D3-dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors.

Authors:  J Barsony; J W Pike; H F DeLuca; S J Marx
Journal:  J Cell Biol       Date:  1990-12       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.